PURPOSE: The causal relationship between breast cancer and its estrogen receptor (ER) subtypes and neutropenia and agranulocytosis is unclear.
METHODS: In two-sample Mendelian randomization (MR), we used inverse variance weighting (IVW), Bayesian weighted MR (BWMR), MR-Egger, weighted median, simple mode, and weighted mode methods to analyze causality for ER-positive breast cancer, ER-negative breast cancer, overall breast cancer, and drug-induced neutropenia and agranulocytosis. To validate the results, we performed the analysis again using GWAS data on neutropenia from different databases. In multivariable MR (MVMR), we assessed the independent effects of ER-positive and ER-negative breast cancer on causality.
RESULTS: Two-sample MR analysis showed a causal relationship between ER-positive breast cancer (IVW odds ratio (OR) = 1.319, P = 7.580 × 10), ER-negative breast cancer (OR = 1.285, P = 1.263 × 10), overall breast cancer (OR = 1.418, P = 2.123 × 10), and drug-induced neutropenia and a causal relationship between ER-positive breast cancer (OR = 1.349, P = 1.402 × 10), ER-negative breast cancer (OR = 1.235, P = 7.615 × 10), overall breast cancer (OR = 1.429, P = 9.111 × 10), and neutropenia. Similarly, ER-positive breast cancer (OR = 1.213, P = 5.350 × 10), ER-negative breast cancer (OR = 1.179, P = 1.300 × 10), and overall breast cancer (OR = 1.275, P = 8.642 × 10) also had a causal relationship with agranulocytosis. MVMR analysis showed that ER-positive breast cancer remained causally associated with drug-induced neutropenia (OR = 1.233, P = 4.188 × 10), neutropenia (OR = 1.283, P = 6.363 × 10), and agranulocytosis (OR = 1.142, P = 4.549 × 10). Heterogeneity analysis and pleiotropy test showed that our results were reliable. -10 -4 -13 -7 -3 -10 -8 -3 -11 -4 -4 -3
CONCLUSION: Our study provides genetic evidence for a causal association between breast cancer and its estrogen receptor subtypes and neutropenia. In clinical practice, in addition to focusing on therapeutic factors, additional attention should be given to breast cancer patients to avoid severe neutropenia.
